Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals plc

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe that the following s...

These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $62.00. Olson co...

Current Quarter	$-0.38	Next Quarter	$-0.37
Current Year	$-1.39	Next Year	$-1.61
QoQ Growth	+2.6%	YoY Growth	-15.8%
3Y EPS CAGR	+32.0%	Target Price	$37.08
Consensus	Buy	Upside	+39.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CNTA	$26.51	-2.47%	2.41M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CNTA	$26.51	-2.5%	2.41M
3
4
5
6

CNTA

CNTA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Centessa Pharmaceuticals plc Data in Excel

Get Centessa Pharmaceuticals plc Data in Excel